On September 27, the healthcare data analytics firm Trilliant Health released a blockbuster report on the volume of prescriptions for GLP-1 weight loss drugs.
The report said that prescriptions for drugs like Ozempic—approved by the FDA in 2017 to treat patients with type 2 diabetes—and Wegovy (for weight loss) increased 300% from the start of 2020 to the end of 2022. U.S. healthcare providers wrote more than 9 million prescriptions for these GLP-1 drugs in the final quarter of 2022, as demand soared for the blockbuster treatments.
The report underscored how the drugs have skyrocketed in popularity since debuting a few years ago.
And one key company is reaping the benefits…
This post originally appeared at Investors Alley.